Chris Williamson
Chris Williamson
AbCellera Biologics
Verified email at abcellera.com
Title
Cited by
Cited by
Year
DNA-repair defects and olaparib in metastatic prostate cancer
J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ...
New England Journal of Medicine 373 (18), 1697-1708, 2015
13182015
ATM deficiency sensitizes mantle cell lymphoma cells to poly (ADP-ribose) polymerase-1 inhibitors
CT Williamson, H Muzik, AG Turhan, A Zamò, MJ O'Connor, DG Bebb, ...
Molecular cancer therapeutics 9 (2), 347-357, 2010
1642010
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
CT Williamson, R Miller, HN Pemberton, SE Jones, J Campbell, A Konde, ...
Nature communications 7 (1), 1-13, 2016
1332016
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
CT Williamson, E Kubota, JD Hamill, A Klimowicz, R Ye, H Muzik, M Dean, ...
EMBO molecular medicine 4 (6), 515-527, 2012
1022012
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
E Kubota, CT Williamson, R Ye, A Elegbede, L Peterson, SP Lees-Miller, ...
Cell Cycle 13 (13), 2129-2137, 2014
912014
Large-scale profiling of kinase dependencies in cancer cell lines
J Campbell, CJ Ryan, R Brough, I Bajrami, HN Pemberton, IY Chong, ...
Cell reports 14 (10), 2490-2501, 2016
812016
Synthetic lethal targeting of ARID1A-mutant ovarian clear cell tumors with dasatinib
RE Miller, R Brough, I Bajrami, CT Williamson, S McDade, J Campbell, ...
Molecular cancer therapeutics 15 (7), 1472-1484, 2016
532016
The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status
M Kim, CT Williamson, J Prudhomme, DG Bebb, K Riabowol, PWK Lee, ...
Oncogene 29 (27), 3990-3996, 2010
502010
Directing the use of DDR kinase inhibitors in cancer treatment
I Brandsma, EDG Fleuren, CT Williamson, CJ Lord
Expert opinion on investigational drugs 26 (12), 1341-1355, 2017
402017
Modeling therapy resistance in BRCA1/2-mutant cancers
A Dréan, CT Williamson, R Brough, I Brandsma, M Menon, A Konde, ...
Molecular cancer therapeutics 16 (9), 2022-2034, 2017
312017
ATR is a therapeutic target in synovial sarcoma
SE Jones, EDG Fleuren, J Frankum, A Konde, CT Williamson, DB Krastev, ...
Cancer research 77 (24), 7014-7026, 2017
242017
DNA-dependent SUMO modification of PARP-1
N Zilio, CT Williamson, S Eustermann, R Shah, SC West, D Neuhaus, ...
DNA repair 12 (9), 761-773, 2013
172013
Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC
LF Petersen, AC Klimowicz, S Otsuka, AA Elegbede, SK Petrillo, ...
Oncotarget 8 (24), 38326, 2017
122017
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
H Holme, A Gulati, R Brough, EDG Fleuren, I Bajrami, J Campbell, ...
Scientific reports 8 (1), 1-9, 2018
62018
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells
EA Lemm, B Valle-Argos, LD Smith, J Richter, Y Gebreselassie, MJ Carter, ...
Clinical Cancer Research 26 (7), 1700-1711, 2020
42020
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
TA Yap, B O'Carrigan, MS Penney, JS Lim, JS Brown, ...
32020
DNA Double Strand Break Repair: Mechanisms and Therapeutic Potential
LM Williamson, CT Williamson, SP Lees-Miller
The DNA Damage Response: Implications on Cancer Formation and Treatment, 157-177, 2009
22009
ATM DEFICIENCY IS ASSOCIATED WITH WORSE OUTCOME IN RESECTED NON-SMALL CELL LUNG CANCER
G Bebb, AC Klimowicz, T Williamson, S Petrillo, J Fralick, S Otsuka, ...
JOURNAL OF THORACIC ONCOLOGY 6 (6), S1108-S1109, 2011
12011
Effect of inhibition of PARP-1 on mantle cell lymphoma cells with dysfunctional ATM
C Williamson, DG Bebb, H Muzik, SP Lees-Miller
Journal of Clinical Oncology 26 (15_suppl), 8584-8584, 2008
12008
Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer
CJ Lord, C Williamson, S Jones
US Patent App. 16/067,994, 2019
2019
The system can't perform the operation now. Try again later.
Articles 1–20